Reevaluating the role of interferon‐beta in psoriasis pathogenesis: A registry‐based self‐controlled study

Interferon‐beta has been suggested as a trigger of psoriasis, yet a systematic investigation is lacking. This study aimed to assess the risk of developing psoriasis following interferon‐beta treatment, utilizing a pharmaco‐epidemiological approach to investigate the role of interferon‐beta in psoria...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2024-08, Vol.51 (8), p.1113-1116
Main Authors: Heerfordt, Ida M., Framke, Elisabeth, Windfeld‐Mathiasen, Josefine, Mogensen, Mette, Olsen, Rasmus Huan, Magyari, Melinda, Horwitz, Henrik
Format: Article
Language:English
Subjects:
Concise Communication
Epidemiology
immunomodulation
inflammatory diseases
Interferon
interferon‐beta
Multiple sclerosis
Pathogenesis
Psoriasis
psoriasis pathogenesis
skin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interferon‐beta has been suggested as a trigger of psoriasis, yet a systematic investigation is lacking. This study aimed to assess the risk of developing psoriasis following interferon‐beta treatment, utilizing a pharmaco‐epidemiological approach to investigate the role of interferon‐beta in psoriasis pathogenesis. We included all treatment‐naïve patients with multiple sclerosis (MS) in Denmark who initiated interferon‐beta treatment for MS from January 1996 to June 2023. These patients were compared to a control cohort of patients with MS treated with other disease‐modifying drugs. We compared the incidence rates of psoriasis before and during the treatment. Data for this study were extracted from the Danish MS Registry and integrated with information from other national Danish health registries. Among 7174 patients treated with interferon‐beta, the incidence rate of psoriasis post‐treatment initiation was slightly higher (2.01 per 1000 person‐years) compared to the rate prior to treatment (1.67 per 1000 person‐years). This increase did not achieve statistical significance (P = 0.53), with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 0.68–2.13). The control cohort showed an increase in psoriasis incidence post‐treatment initiation (3.12 per 1000 person‐years) compared to prior (1.11 per 1000 person‐years), with an IRR of 2.80 (95% CI 1.36–4.77, P = 0.0038). This registry‐based self‐controlled study does not support the theory that interferon‐beta acts as a trigger for psoriasis development.
ISSN:0385-2407
1346-8138
1346-8138
DOI:10.1111/1346-8138.17338